New drug miricorilant tested for fatty liver disease safety
Knowledge-focused
Not yet recruiting
This early-stage study tests the safety and how the body processes the drug miricorilant in 15 adults with MASH, a serious fatty liver condition. Participants will take the drug and be monitored for side effects and drug levels in the blood. The goal is to gather information for …
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 02:00 UTC